Publications

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Garabrant DH, Pastula ST. 2018. A comparison of asbestos fiber potency and elongate mineral particle (EMP) potency for mesothelioma in humans. Toxicol Appl Pharmacol 361(15 Dec):127–136; doi: 10.1016/j.taap.2018.07.003.

Movva N, Jani A. 2018. The value of pay-for-performance in England: An evaluation of NHS England’s Quality Outcomes Framework. University of Oxford Research Archive, no. 2.

Olson A, Frankenfeld CL, Wallace TC, Johnson J. 2018. Assessment of oats and milk on markers of cardiovascular disease: NHANES 1999-2014 datasets. Nutr Today 53:293–299; doi: 10.1097/NT.0000000000000308.

Mullins M, Jiang X, Bylsma LC, Fryzek JP, Reichert H, Chen EC, Kummar S, Rosenthal A. 2017. Cold agglutinin disease burden: A longitudinal analysis of anemia, medications, transfusions, and healthcare utilization. Blood Adv 1:839-848.

Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. 2017. Arteriovenous fistulas for hemodialysis: A systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg 54:513e522.

Friedman D, Fryzek J, Jiang X, Bloomfield A, Ambrose CS, Wong PC. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One. 2017 Mar 2;12(3):e0172512.

Pastula S, Hackett J, Coalson J, Jiang X, Villafana T, Fryzek J. 2017. Hospitalizations for Respiratory Syncytial Virus among adults in the United States, 1997 to 2012.  2017. Open Forum Infectious Diseases 4(1):ofw270.

Alexander DD, Miller PE, van Elswyk M, Kuratko C, Bylsma L. 2017. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long chain omega-3 fatty acids and coronary heart disease risk. Mayo Clinic Proceedings 92(1):15-29; doi: 10.1016/j.mayocp.2016.10.018.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130:5615.